ALUMIS INC. (ALMS)

Current Report Filed: 2026-03-30

Alumis reported positive topline results from two Phase 3 trials of its lead drug candidate envudeucitinib for the treatment of plaque psoriasis, showing early and robust improvements in skin clearance, quality of life, and psoriasis symptoms.
The company plans to submit a New Drug Application (NDA) for envudeucitinib in the second half of 2026, which could potentially transform the treatment landscape for IL-23/IL-17-driven diseases as well as those driven by Type I interferon.
Alumis expects to have one-year Phase 3 long-term data available in the second half of 2026 and is also developing a once-daily formulation and a pediatric development plan for envudeucitinib, further expanding its commercial potential.

Current Report Filed: 2026-03-19

Alumis Inc. reported its financial results for the year ended December 31, 2025, indicating the company's performance during the previous fiscal year.
The filing does not provide any details on the company's financial results or other material information, limiting the ability to assess the company's current state and future prospects.
Without further details on the company's operational and financial performance, it is difficult to determine the overall significance of this filing for investors.

Annual Report Filed: 2026-03-19

Alumis Inc. has recently completed an IPO and private placement, raising significant additional capital to fund its operations and growth initiatives.
The company has entered into a collaborative arrangement with Kaken Pharmaceutical Co. Ltd. for the development and commercialization of its lead product candidate, Esk001, which could provide a significant revenue stream and further strengthen its financial position.
The company has made investments in property, plant, and equipment, including software development, leasehold improvements, and laboratory equipment, to support its ongoing research and development activities.

Insider Trading Filed: 2026-01-13

Srinivas Akkaraju, a director of Alumis Inc. (ALMS), acquired 588,235 shares of the company's common stock at $17 per share through his investment funds Samsara Opportunity Fund, L.P. and Samsara BioCapital, L.P.
This insider buying activity suggests that Akkaraju is bullish on Alumis and believes the stock is undervalued at the current price.
With Akkaraju's increased ownership of over 6.3 million shares, representing a significant stake in the company, his interests are now further aligned with those of other shareholders.

Insider Trading Filed: 2026-01-12

The reporting person, James B. Tananbaum, has acquired a significant stake in ALUMIS INC. (ALMS) through multiple investment funds and entities under his control.
Tananbaum has acquired a total of over 10 million shares, representing a substantial ownership position of more than 10% in the company.
The reported transactions indicate a concentration of insider buying activity, which could signal confidence in the company's future prospects.

Insider Trading Filed: 2026-01-12

Foresite Capital, a prominent venture capital firm, has significantly increased its stake in Alumis Inc. through multiple transactions, indicating strong confidence in the company's prospects.
The reported purchases of over 400,000 shares at $17 per share suggest Foresite Capital believes Alumis is undervalued and has significant upside potential.
Foresite Capital's position as a 10% owner and the inclusion of several of its affiliated entities as reporting persons suggests a coordinated, long-term investment strategy in Alumis.

Insider Trading Filed: 2026-01-12

Foresite Labs, LLC and its affiliates have significantly increased their ownership stake in ALUMIS INC. (ALMS), now holding over 10% of the company's shares.
The majority of the shares were acquired through open market purchases at $17 per share, indicating the investor group's confidence in the company's prospects.
The reporting of these transactions in a timely manner suggests that Foresite Labs and its affiliates are closely monitoring their investment in ALUMIS INC.

Current Report Filed: 2026-01-09

Alumis Inc. reported preliminary unaudited cash, cash equivalents and marketable securities of approximately $308.6 million as of December 31, 2025, providing insight into the company's strong liquidity position.
Alumis announced a public offering of 17,650,000 shares of its common stock at $17.00 per share, raising approximately $345.1 million in gross proceeds before deductions, which will strengthen the company's financial flexibility.
The company granted the underwriters an option to purchase up to an additional 2,647,500 shares, which was exercised in full, further increasing the total capital raised through the offering.

Current Report Filed: 2026-01-02

Alumis Inc. has filed an 8-K report indicating a material breach by its partner Climb Bio, who has failed to make a $3 million development milestone payment as required under their asset purchase agreement.
Alumis intends to pursue all available legal rights and remedies against Climb Bio, including seeking the overdue payment, interest, and reimbursement of legal fees.
The dispute appears to center around Climb Bio's claim that its drug candidate 'budoprutug' does not qualify as a 'Product' under the agreement, contrary to Climb Bio's own prior statements.

Important Information